Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Akselerert bilateral rTMS på geriatrisk depresjon

15. november 2026 oppdatert av: National Taiwan University Hospital

Terapeutisk effekt av akselerert bilateral gjentatt transkraniell magnetisk stimulering på geriatrisk depresjon: en prospektiv dobbeltblind, randomisert kontrollert prøvelse

This study aims to evaluate the efficacy of accelerated bilateral repetitive transcranial magnetic stimulation (rTMS) on major depression, anxiety, cognitive function and physiological parameters in elderly depressive patients.

Studieoversikt

Detaljert beskrivelse

Repeated transcranial magnetic stimulation (rTMS) is a non-invasive brain stimulation treatment, showing good therapeutic effect to medicine treatment-refractory patients. Recent studies suggested bilateral DLPFC might be effective to geriatric depression. Accelerated treatment course was reported to have similar therapeutic effect and safety profile with traditional course. The investigators hypothesize accelerated bilateral rTMS is effective to geriatric depression and comorbid anxiety.

Cognitive impairment and decreased parasympathetic tone are common in patients with major depression. The investigators hypothesize cognitive function and physiological indicators improve after accelerated bilateral rTMS.

In this single-center, prospective double-blind, randomized, active-controlled trial, the investigators aim to recruit 100 patients older than 60 years, without neurocognitive disorders, and refractory to one or more antidepressants. The experimental group would receive an rTMS course with high-frequency stimulation at left DLPFC followed by low-frequency inhibition at right DLPFC, two sessions daily, five days a week, and two weeks in total. The standard treatment group would receive an rTMS course with high-frequency stimulation at left DLPFC as standard treatment parameters. Mood, cognition and physiological markers would be monitored every week. The primary outcome is response and remission rate of major depression measured by Hamilton Rating Scale for Depression.

Studietype

Intervensjonell

Registrering (Faktiske)

2

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

      • Douliu, Taiwan
        • Department of Psychiatry, National Taiwan University Hospital, Yun-Lin Branch

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

60 år til 85 år (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • age between 60-85 years
  • literate and received basic education for at least 2 years
  • diagnosis of major depressive disorder, without psychotic features, according to DSM-5
  • have a score of 20 or greater on the 17-item Hamilton Depression Rating Scale
  • failed to achieve clinical response by at least 1 antidepressant trial of sufficient dosage for at least 4 weeks
  • psychoactive agents were in stable doses before randomization

Exclusion Criteria:

  • active suicide plans or attempts; or suicide attempts in the last 12 months
  • diagnosis of schizophrenia or bipolar disorder according to DSM-5
  • have DSM-5-confirmed substance use disorder (excluding tobacco) in the last 3 months
  • have delirium, major neurocognitive disorder or MMSE < 24
  • current use of bupropion >300 mg/day, tricyclic antidepressant, clozapine, chlorpromazine, foscarnet, ganciclovir, ritonavir, theophylline or anti-epileptic agents excluding benzodiazepines
  • history of severe head trauma, epilepsy, multiple sclerosis, stroke, brain tumors, intracranial aneurysm, active intracranial infection, increased intracranial pressure, metallic implants in the brain, major brain surgery or major neurological diseases
  • with a cardiac pacemaker or defibrillator
  • received rTMS treatment before

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Trippel

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Experimental Group

The experimental group would receive an rTMS course with high-frequency stimulation (10Hz) at left DLPFC (120% motor threshold, 40 trains, 1600 pulses) followed by low-frequency (1Hz) inhibition at right DLPFC (120% motor threshold, 10 trains, 1200 pulses), two sessions daily with a 1.5-hour inter-session interval (L't active-R't active-1.5 hr-L't active-R't active), five days a week, and two weeks in total.

Magstim® Super Rapid² Transcranial Magnetic Stimulation System

Aktiv komparator: Standard Treatment Group

The standard treatment group would receive an rTMS course with high-frequency stimulation (10Hz) at left DLPFC (120% motor threshold, 40 trains, 1600 pulses) followed by sham inhibition at right DLPFC (1Hz, 10 trains, 1200 pulses); after a 1.5-hour inter-session interval, a sham session would be administered at left and right DLPFC (L't active-R't sham-1.5 hr-L't sham-R't sham. The course would be applied five days a week, and two weeks in total.

Magstim® Super Rapid² Transcranial Magnetic Stimulation System

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Degree of Change in 17-item Hamilton Depression Rating Scale (HAM-D 17)
Tidsramme: day 1, day 5, day 12, day 19

HAM-D 17 is a scale rating the severity of depression, covering emotional, cognitive and somatic symptoms of depression. Higher scores indicate higher severity. Response to treatment is defined as ≥ 50% decrease in HAM-D 17; remission is defined as ≤ 7 points in HAM-D 17.

day 1, day 5, day 12, day 19

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Degree of Change in Hamilton Anxiety Rating Scale (HAM-A)
Tidsramme: day 1, day 5, day 12, day 19

HAM-A is a scale rating the severity of anxiety, covering emotional, cognitive and somatic symptoms of anxiety. Higher scores indicate higher severity.

day 1, day 5, day 12, day 19
Degree of Change in Mini-Mental State Examination (MMSE)
Tidsramme: day 1, day 5, day 12, day 19

MMSE is a wildly-used tool to evaluate several cognitive function domains.

day 1, day 5, day 12, day 19
Degree of Change in Stroop Test
Tidsramme: day 1, day 5, day 12, day 19

Task 1 (word phase) requests a subject to say a color name string (red, green, blue) printed in black; Task 2 (color phase) requests a subject to say the printed colors (red, green, blue) of letter "x" string; Task 3 (interference phase) requests a subject to say the printed colors of a string of color names (red, green, blue).

day 1, day 5, day 12, day 19
Degree of Change in Trail Making Test
Tidsramme: day 1, day 5, day 12, day 19

Task 1 requests a subject to connect a sequence of 25 consecutive numbers regardless of their colors; Task 2 requires a subject to connect 25 consecutive numbers in alternative colors.

day 1, day 5, day 12, day 19
Degree of Change in Verbal Fluency Test
Tidsramme: day 1, day 5, day 12, day 19

This test requests a subject to speak as many names of vegetables, fishes or fruit as possible in 45 seconds.

day 1, day 5, day 12, day 19
Degree of Change in Physiological Parameters
Tidsramme: day 1, day 5, day 12, day 19

ProComp5 Infiniti (SA7525) Biofeedback System would be used. Heart rate variability, skin conductance, body temperature and respiratory rate would be measured.

day 1, day 5, day 12, day 19

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

23. november 2020

Primær fullføring (Faktiske)

21. desember 2022

Studiet fullført (Faktiske)

21. desember 2022

Datoer for studieregistrering

Først innsendt

15. juli 2020

Først innsendt som oppfylte QC-kriteriene

22. juli 2020

Først lagt ut (Faktiske)

24. juli 2020

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

18. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

15. november 2026

Sist bekreftet

1. mai 2021

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere